A multicenter, randomized, parallel-groups, double-blind placebo-controlled study comparing the efficacy, safety, and tolerability of administration of ezetimibe/simvastatin tablet 10/20 mg versus doubling the dose of simvastatin 20 mg [simvastatin 40 mg] in subjects with primary hypercholesterolemia and coronary heart disease

Trial Profile

A multicenter, randomized, parallel-groups, double-blind placebo-controlled study comparing the efficacy, safety, and tolerability of administration of ezetimibe/simvastatin tablet 10/20 mg versus doubling the dose of simvastatin 20 mg [simvastatin 40 mg] in subjects with primary hypercholesterolemia and coronary heart disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 May 2017

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
  • Indications Coronary disorders; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jun 2008 Status changed from in progress to completed.
    • 21 Mar 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top